



Poietis

make tissues real

For immediate release

Poietis, the 4D bioprinting company, announces the issuance in the United States and Japan of two major patents on bioprinting

Pessac, France, June 24th, 2015– Poietis, first French bioprinting company today announced the issuance by the American Patent Office (USPTO) and the Japanese Office (JPO) of two patents covering its 3D laser assisted bioprinting technology.

“ The issuance of these patents both in the USA and Japan is very good news. These decisions lays the foundation for future industrial exploitation in these two important countries, that represent together a very large part of the regenerative medicine market ” said Bruno Brisson, Poietis co-founder and Director of Business Development.

US Patent 9,039,998 dated May 26, 2015 and JP 2012-555441 dated May 01, 2015 were issued at INSERM and are part of the patent portfolio Poietis holds the exclusive rights for all applications pursuant to a license agreement signed in December 2014 with INSERM, the University of Bordeaux and Aquitaine Science Transfert©, SATT Aquitaine.

“ These patents are the result of a research work initially conducted in collaboration with clinicians from INSERM and the University of Bordeaux on in situ bioprinting. This innovative approach, which allows to adapt the printing pattern with the characteristics of the substrate, paves the way for the bioprinting in vivo, i.e. directly on a patient ” said Dr. Fabien Guillemot, Founder and President of Poietis and pioneer of 3D bioprinting .

The patents entitled "BIOPRINTING STATION, STATION ASSEMBLY COMPRISING SUCH BIOPRINTING BIOPRINTING AND METHOD" describe : *“a Bioprinting station comprising: -a Bioprinting device adapted to deposit a pattern of biological material onto an area of interest of a substrate, -an imaging system adapted to acquire an image of the substrate and to reveal on the acquired image the area of interest with respect to a remaining part of the substrate, the acquired image of the substrate being processed so as to detect the revealed area of interest on the acquired image and to determine the pattern corresponding to the area of interest detected on the acquired image. Bioprinting station comprising: -a Bioprinting device adapted to deposit a pattern of biological material onto an area of interest of a substrate, -an imaging system adapted to acquire an image of the substrate and to reveal on the acquired image the area of interest with respect to a remaining part of the substrate, the acquired image of the substrate being processed so as to detect the revealed area of interest on the acquired image and to determine the pattern corresponding to the area of interest detected on the acquired image.”*

About Poietis: Founded in September 2014 following a project incubated for 2 years at the Aquitaine Regional Incubator and after winning the National Competition of Creation of Innovative Technology Companies, Poietis will value the research work conducted by INSERM and the University of Bordeaux by developing and using the innovative laser-assisted bioprinting technology to design, develop and manufacture biological tissues. This innovative technology operates on the principles of 3D printing and proceeds by layer-by-layer assembly of the constituents of biological tissues according to predefined 3D digital design organizations. The exclusive uses of this technology allow Poietis to produce more complex, robust and customizable tissues than the ones currently obtained by the conventional methods of cell culture and tissue engineering.

The first business model Poietis is to develop and manufacture both catalogue and custom biological tissues for the cosmetics and pharmaceutical industries. In a second step Poietis will address individualized medicine with the production of disease models from patient cells (evaluation of personalized treatments and stratification of patients). Finally the company has the ambition to go to clinic targeting the regenerative medicine market and will offer custom grafts manufacturing service to the growing needs of tissue transplants such as skin and cornea.